SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Contemporary halftone collage. Concept of mobile apps and services, online communication, social media,rating.Business creative illustrat. Vector illustration
Policy
Trump’s Whiplash Tariffs and HHS Layoffs Set Biopharma Industry Ablaze
As the biopharma industry grapples with the uncertain macro environment brought on by the new administration, CEOs, regulators and many others speak out.
April 11, 2025
 · 
3 min read
 · 
BioSpace Editorial Staff
US Capitol_Andrea Izzotti_Adobe Stock
Government
Lawmakers Seek to Boost US Biotech Sector, Keep China’s Growth in Check
According to analysts at Jefferies, legislation such as the newly proposed bills that aim to streamline regulatory processes would be a positive for the biotech industry.
April 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Marburg, Germany - July 6, 2013: Marburg Office of Swiss multinational company Novartis AG
Manufacturing
Novartis Pledges $23B Boost to US Ops as Trump Intensifies Tariff Threats
Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The new facilities will include a biomedical research hub in California, two radioligand plants, and four manufacturing sites.
April 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Exterior view of the headquarters of the
FDA
FDA To Replace Some Animal Testing With AI, Human ‘Organoid’ Lab Models
Analysts at William Blair expect drug developers will continue to perform “at least some animal testing” on their investigational products. Though the process to phase out animal testing will begin “immediately,” no specific timetable was given.
April 11, 2025
 · 
2 min read
 · 
Tristan Manalac
LED Display - Airport flight status board
Regulatory
Biotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA Cuts
Biotech companies are already seeing regulatory delays and plenty of uncertainty after around 3,500 FDA employees were cut by the Trump administration.
April 10, 2025
 · 
3 min read
 · 
Annalee Armstrong
The concept of crisis management. stock photo
Tariffs
Trump Tariff Pause Sparks Late-Day Rally for Pharma Stocks—But Not All
Pharma stocks went on a wild ride Wednesday amid whiplashing tariff threats from the U.S. president.
April 10, 2025
 · 
2 min read
 · 
Annalee Armstrong
Funding
Tempest Scrambles for Ways to Bankroll Late-Stage Liver Cancer Asset
According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.
April 10, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH DIA
Breaking Down Barriers: The Nuanced Approach to Women’s Representation in Medical Research
In this episode presented by DIA, BioSpace’s head of insights Lori Ellis discusses the underrepresentation of women in clinical trials with Martin Hodosi, partner at Kearney and Melissa Laitner, director of strategic initiatives at the National Academy of Medicine.
April 10, 2025
 · 
1 min read
 · 
Lori Ellis
Blindness and crisis, blindfolded businessman walks to the cliff
FDA
Threat to FDA User Fees Program Could Set US Back 35 Years
Experts express concern that last week’s unprecedented FDA layoffs will trigger a little-known mechanism that could result in a “disaster” the Trump administration doesn’t see coming.
April 10, 2025
 · 
5 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS